BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2006

View Archived Issues

Pharmexa updates pipeline progress

Read More

BMS-275291 well tolerated in hormone-refractory prostate cancer

Read More

Continual paroxetine therapy reduces depression recurrence in the elderly

Read More

Renal effects of ISIS-113715 investigated in monkeys

Read More

ES-285 adminstration feasible when given once every 3 weeks in cancer patients

Read More

Pooled studies show efficacy of duloxetine in diabetic peripheral neuropathic pain

Read More

AC-100 enhances bone formation in tooth extraction model

Read More

Albumin can safely reduce interferon alpha clearance in hepatitis C patients

Read More

BMS-587101: new LFA-1 antagonist in phase II study for psoriasis

Read More

New TRPV1 antagonists for pain profiled at ACS meeting

Read More

Ono and Medarex collaborate on development of anti-SDF-1 antibodies

Read More

Medarex grants full European commercialization rights for DTS-201 to Diatos

Read More

SGX and Novartis team up on Bcr-Abl inhibitors for drug-resistant CML

Read More

Phase I study begins for PulmoLAR

Read More

Dynavax to acquire Rhein Biotech GmbH

Read More

Phase Ib study under way for neurodegenerative compound AL-208

Read More

Positive findings for phase IIb study of Pollinex Quattro Ragweed vaccine

Read More

PanGenetics closes series B financing

Read More

BioBalance to begin clinic trials of Probactrix for pouchitis

Read More

Phase I trial cleared to study dendritic cell strategy in treatment of diabetes

Read More

Seretide reduces mortality in COPD patients

Read More

New adenosine A2A antagonist from Schering-Plough in phase II for Parkinson's

Read More

New treatment options reported for thrombotic disorders

Read More

Novel compounds with potential for the treatment of neurological disorders disclosed

Read More

Recent patents claim agents for gastrointestinal disorders

Read More

Axcan submits NDA amendment for Helizide

Read More

Galvus NDA accepted for review

Read More

Swiss approval for Nexavar in advanced kidney cancer

Read More

Synthesis of novel himbacine-based PAR-1 antagonists reported

Read More

Pfizer presents preclinical and clinical data on novel TAFI inhibitor

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing